A detailed history of Center Book Partners LP transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Center Book Partners LP holds 5,976 shares of PTGX stock, worth $277,644. This represents 0.02% of its overall portfolio holdings.

Number of Shares
5,976
Holding current value
$277,644
% of portfolio
0.02%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$33.72 - $47.33 $201,510 - $282,844
5,976 New
5,976 $268,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.28B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Center Book Partners LP Portfolio

Follow Center Book Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Center Book Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Center Book Partners LP with notifications on news.